Pfizer for Professionals Pfizer for Professionals




Pfizer Medical Information
(Search Medical Responses)
WyethHCP.com
(Access Wyeth for Professionals)
Explore Other Online Resources
ppn-vr-sso-links.htm
To report an adverse event or to speak to a member of Pfizer Medical Information, please call 1-800-438-1985

Share Your Feedback
Prescribing Information
NORVASC® (amlodipine besylate) Tablets
Warnings
Return to the NORVASC Product Center

Increased Angina and/or Myocardial Infarction: Rarely, patients, particularly those with severe obstructive coronary artery disease, have developed documented increased frequency, duration and/or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase. The mechanism of this effect has not been elucidated.


NORVASC Indication and Important Safety Information
 

Please scroll to see the Indication below.

Important Safety Information

NORVASC is indicated for the treatment of hypertension and angina.

In clinical trials, the most common side effects versus placebo were edema (8.3% vs 2.4%), headache (7.3% vs 7.8%), fatigue (4.5% vs 2.8%), and dizziness (3.2% vs 3.4%).

Generally CCBs should be used with caution in patients with heart failure. In studies with NORVASC, there has been no evidence of worsened heart failure.

 

Indication

Amlodipine

1, Hypertension: Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents;

2. Coronary Artery Disease (CAD)
Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents;
Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs.
Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure.

Please see full prescribing information.

NORVASC ® (amlodipine besylate)

Back to Top

SetPProProdListVar.htm
SetPFPGroupVar.htm